Coherus BioSciences

Health bioengineering biotech drug development

Coherus BioSciences is engaged in developing and commercializing biosimilar drugs of the highest quality and value. The Company’s product candidates include CHS-1701, drug pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma.

Revenue(FY, 2017)

$1.6 M

Market capitalization(2018-04-20)

$633.1 M

Type

Public

Redwood City, US

Founded

2010

Size (employees)

127 (est)-3%

Website

coherus.com

Coherus BioSciences was founded in 2010 and is headquartered in Redwood City, US

Report incorrect company information

Coherus BioSciences Office Locations

Coherus BioSciences has an office in Redwood City

Redwood City, US (HQ)

600 333 Twin Dolphin Dr

Show all (1)

Report incorrect company information

Coherus BioSciences Financials and Metrics

Coherus BioSciences Financials

Coherus BioSciences's revenue was reported to be $1.56 m in FY, 2017

Summary

USD
Revenue (FY, 2017)	1.6 m
Net income (FY, 2017)	(238.3 m)
EBIT (FY, 2017)	(232.1 m)
Market capitalization (20-Apr-2018)	633.1 m
Cash (31-Dec-2017)	126.9 m

Coherus BioSciences's current market capitalization is $633.1 m.

Income Statement

Annual

USD	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Revenue	31.1 m	30 m	190.1 m	1.6 m
Revenue growth, %		(3%)	533%
General and administrative expense	17.6 m	36 m	51.6 m	71.3 m
R&D expense	78.2 m	213.1 m	254.4 m	162.4 m

Quarterly

USD	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Revenue					12.4 m	14.1 m
General and administrative expense	4 m	6.1 m	8.8 m	10.2 m	11.4 m	11.3 m	13.6 m	18.8 m	23.5 m
R&D expense	18.5 m	36.5 m	56.9 m	68.2 m	65.3 m	65.5 m	64.6 m	53.8 m	34.5 m
Operating expense total	22.5 m	42.6 m	65.8 m	78.4 m	76.7 m	76.8 m	78.2 m	72.6 m	58 m

show all

Balance Sheet

Annual

USD	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	150.4 m	158.2 m	124.9 m	126.9 m
Inventories			1.9 m
Current Assets	179.1 m	197.4 m	161.5 m	145.5 m
PP&E	4.5 m	10.5 m	10.8 m	12.8 m

Quarterly

USD	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Cash	100.9 m	115.1 m	206.1 m	153.7 m	179.6 m	220.9 m	159.7 m	124.9 m	73.4 m
Current Assets	118.9 m	143.9 m	239.6 m	189.3 m	211.6 m	236.8 m	177.3 m	208.3 m	153.3 m
PP&E	3.7 m	5.1 m	6.3 m	8.7 m	10.3 m	9.9 m	10.7 m	14.9 m	14.5 m
Goodwill	943 k	943 k	943 k	943 k	943 k	943 k	943 k	943 k	943 k

show all

Cash Flow

Annual

USD	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(87.2 m)	(223.9 m)	(127.8 m)	(238.3 m)
Depreciation and Amortization	674 k		3 m	3.4 m
Accounts Payable	3.6 m		(5 m)	(3.8 m)
Cash From Operating Activities	(23.9 m)		(252.5 m)	(200.3 m)

Quarterly

USD	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Net Income	(7.9 m)	(40.8 m)	(99.9 m)	(171.4 m)	(65.5 m)	(135.7 m)	(51.8 m)	(74.8 m)	(130.2 m)
Depreciation and Amortization			632 k	1.3 m	717 k	1.4 m	2.2 m	865 k	1.7 m
Accounts Payable	4.4 m	10.9 m	7.1 m	19.1 m	(6.8 m)	(7.4 m)	(1.6 m)	(7.3 m)	(3.8 m)
Cash From Operating Activities			(53.9 m)	(113.6 m)	(76.3 m)	(103.7 m)	(165.7 m)	(73.3 m)	(128.9 m)